Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
There is a high risk of transmission of COVID-19 to healthcare workers. In a recent cohort, 29% of the patients hospitalized were healthcare workers. Among the WHO's primary strategic objectives for the response to COVID-19, the first was to limit human-to-human transmission, including reducing secondary infections among close contacts and health care workers. Automated oxygen titration, weaning and monitoring (FreeO2 device) may be a solution to reduce the number of interventions of healthcare workers related to oxygen therapy, to reduce complications related to oxygen and to improve monitoring.
Description: The number of interventions required by healthcare workers to manage oxygen therapy (titration, weaning and monitoring) during 4 hours
Measure: The number of interventions Time: Hour0 to Hour4Description: The number of interventions required by healthcare workers to manage oxygen therapy (titration, weaning and monitoring) during 4 hours
Measure: Duration of interventions Time: Hour0 to Hour24Description: The Mean oxygen flow during study duration to evaluate oxygen consumption
Measure: Mean oxygen flow Time: Hour0 to Hour24 (1 day)Description: Time within SpO2 between 90 and 94%
Measure: Time within theSpO2 target Time: Hour0 to Hour24 (1 day)Description: Time within SpO2 < 88%
Measure: Time with hypoxemia Time: Hour0 to Hour24 (1 day)Description: Time within SpO2 > 96%
Measure: Time with hyperoxemia Time: Hour0 to Hour24 (1 day)Description: Rate of ICU admission
Measure: Rate of ICU admission Time: Hour0 to Hour24 (1 day)Description: Rate of needed non invasive respiratory support Non invasive ventilation or High Flow Nasal Therapy
Measure: Rate of needed non invasive respiratory support Time: Hour0 to Hour24 (1 day)Description: Rate of intubation
Measure: Rate of intubation Time: Hour0 to Hour24 (1 day)Description: Evaluation of NEWS 2 score evolution (National Early Warning score) correlate to patient evolution. The NEWS2 score will be calculate but no intervention will be made based on this score. Patient evolution will be compare at NEWS 2 interpretation. Interpretation A low score (NEWS 1-4) should prompt assessment by a competent registered nurse who should decide if a change to frequency of clinical monitoring or an escalation of clinical care is required. A medium score (ie NEWS of 5-6 or a RED score) should consider whether escalation of care to a team with critical-care skills is required (ie critical care outreach team). A high score (NEWS ≥7) should prompt emergency assessment by a clinical team/critical care outreach team with critical-care competencies and usually transfer of the patient to a higher dependency care area.
Measure: NEWS 2 score evolution Time: Hour0 to Hour24 (1 day)Description: Evaluation of EWSO2 score(Early Warning ScoreO2) evolution correlate to patient evolution The EWSO2 score will be calculate but no intervention will be made based on this score. Patient evolution will be compare at EWSO2 interpretation. Interpretation Favorable clinical outcome in patients with a score <5.3 A patient with a score >18.6 will experience a poor outcome.
Measure: EWSO2 score evolution Time: Hour0 to Hour24 (1 day)Description: Cost effectiveness ratio (cost per SpO2 unit)
Measure: Cost-effectiveness Time: From date of randomization until the date of hospital dischargeDescription: Duration of the hospital length of stay
Measure: length of stay Time: up to 90 days. Hospital stay - hospital admission through hospital discharge or until death if occuredAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports